Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Key Highlights
- ➤6-point EQ-VAS increase established as clinically meaningful in tardive dyskinesia
- ➤INGREZZA delivered mean 13.1-point EQ-VAS improvement at Week 24
- ➤TDIS and AIMS improvements exceeded clinical thresholds by Weeks 8 and 4
- ➤Three Neurocrine analyses will be presented at AMCP Nexus 2026
Expert Statements
Eiry W. Roberts, Chief Medical Officer, Neurocrine Biosciences
“Patient-reported outcomes provide an important perspective on how tardive dyskinesia and its treatment affect patients beyond changes in involuntary movements alone,”
Eiry W. Roberts, Chief Medical Officer, Neurocrine Biosciences
“Establishing what represents a clinically meaningful change in patients' overall health can help clinicians better interpret patient-reported improvements in quality of life and builds on the established body of evidence demonstrating the broader impact of treating tardive dyskinesia with INGREZZA.”
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia PR Newswire
* New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA(®)(valbenazine) capsules * The 6-point threshold helps contextualize the meaningful improvement with INGREZZA observed in the KINECT-PRO™ study, including a mean 13.1-point improvement in EQ Visual Analogue Scale scores, and complements established measures of tardive dyskinesia-specific impact and movement severity * Findings are among three Neurocrine Biosciences analyses to be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference SAN DIEGO, Oct. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with INGREZZA(®) (valbenazine) capsules (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804718-1&h=1890335442&u=https%3A%2F%2Fwww.ingrezza.com%2Ftardive-dyskinesia&a=INGREZZA%C2%AE%C2%A0(valbenazine)+capsules) . The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, taking place Oct. 26-29 in San Diego.
Get started
Create a free account to read the full story.